Effects on mouse uterus of three antitumoral drugs acting upon estrogen and progesterone receptors directly and through other transduction pathways

Biochemical Pharmacology

Volumn 55, Issue 3, 1998, Pages 273-278

  Actis, Andrea M ^a   Dorfman, Veronica B ^a   Caruso, Silvana P ^a   Levin, Emanuel ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Antitumor drugs on uterus; Combined drugs on uterus; Cross talk pharmacology; Transduction pathway pharmacology; Uterine pharmacology; Uterine steroid receptors

Indexed keywords

8 CHLOROADENOSINE 3',5' PHOSPHATE; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; RECEPTOR SUBTYPE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOCHEMISTRY; DRUG EFFECT; ESTRUS CYCLE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; SUBCUTANEOUS DRUG ADMINISTRATION; UTERUS; UTERUS WEIGHT;

8-BROMO CYCLIC ADENOSINE MONOPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; FEMALE; MEDROXYPROGESTERONE 17-ACETATE; MICE; MICE, INBRED BALB C; ORGAN SIZE; OVARY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TAMOXIFEN; UTERUS;

EID: 0032008105     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00458-9     Document Type: Article

References (39)

1. Jensen EV, Suzuki T, Tawashima T, Stumpf WE, Junblut PW, DeSombre ER. A two-step mechanism for the interaction of estradiol with rat uterus. Proc Natl Acad Sci USA. 59:1968;632-638.
2. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway Potential origin for the cell-specific estrogen-like effects of antiestrogens . Mol Endocrinol. 9:1995;443-456.
3. Panutti F, Martoni A, Zamagni C, Melotti B. Progestins I Medroxyprogesterone acetate . Powles TJ, Smith IE. Medical Management of Breast Cancer. 1993;95-103 University Press, Cambridge.
4. Cho-Chung YS, Clair T, Tortora G, Yokozaki H. Role of site-selective cAMP analogs in the control and reversal of malignancy. Pharmacol Ther. 50:1991;1-33.
5. Langeveld CH, Jongenelen CAM, Theeuwes JWM, Baak JPA, Heimans JJ, Stoof JC, Peters GJ. The antiproliferative effect of 8-chloro-adenosine, an active metabolite of 8-chloro-cyclic adenosine monophosphate, and disturbances in nucleic acid synthesis and cell cycle kinetics. Biochem Pharmacol. 53:1997;141-148.
6. Actis AM, Caruso SP, Levin E. Opposite effect of a cAMP analogue on tumoral growth related to hormone dependence of a murine mammary tumor. Cancer Lett. 96:1995;81-85.
7. Lanari C, Molinolo AA, Pasqualini CD. Induction of mammary adenocarcinomas by medroxyprogesterone acetate in BALB/c female mice. Cancer Lett. 33:1986;215-223.
8. Actis AM, Caruso SP, Levin E. Estrogen receptor isoforms and progestin hormone dependence in a mouse mammary tumor model. Int J Cancer. 58:1994;668-671.
9. Jordan VC. Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res Treat. 31:1994;41-52.
10. Aronica SM, Kraus WL, Katzenellenbogen BS. Estrogen activation via the cAMP signaling pathway Stimulation of adenylate cyclase and cAMP-regulated gene transcription . Proc Natl Acad Sci USA. 91:1994;8517-8521.
11. Landers JP, Spelsberg TC. New concepts in steroid hormone action Transcription factors, proto-oncogenes and the cascade model for steroid regulation of gene expression . Crit Rev Eukaryot Gene Expr. 2:1992;19-63.
12. Freiss G, Prébois C, Vignon F. Control of breast cancer cell growth by steroid and growth factors Interactions and mechanisms . Breast Cancer Res Treat. 27:1993;57-68.
13. Orti E, Bodwell JE, Munck A. Phosphorylation of steroid hormone receptors. Endocr Rev. 13:1992;105-128.
14. Curtis SW, Korach KS. Uterine estrogen receptor-DNA complexes Effects of different ERE sequences, ligands, and receptor forms . Mol Endocrinol. 5:1991;959-966.
15. Truss M, Beato M. Steroid hormone receptors Interaction with deoxyribonucleic acid and transcription factors . Endocr Rev. 14:1993;459-479.
16. Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation and suppression of malignancy New approaches to therapy . Cancer Res. 50:1990;7093-7100.
17. de Grot RP, Sassone-Corsi P. Hormonal control of gene expression Multiplicity and versatility of cyclic adenosine 3′,5′-monophosphate-responsive nuclear regulators . Mol Endocrinol. 7:1993;145-153.
18. Le Goff P, Montano M, Schodin DJ, Katzenellenbogen BS. Phosphorylation of the human estrogen receptor Identification of hormone-regulated sites and examination of their influence on transcriptional activity . J Biol Chem. 269:1994;4458-4466.
19. Beck CA, Weigel NL, Edwards DP. Effects of hormones and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding and phosphorylation of human progesterone receptors. Mol Endocrinol. 6:1992;607-620.
20. Roesler WJ, Vandenbark GR, Hanson RW. Cyclic AMP and the induction of eukaryotic gene transcription. J Biol Chem. 263:1988;9063-9066.
21. Cho-Chung YS. Site-selective 8-chloro-cyclic adenosine 3′,5′-monophosphate as a biological modulator of cancer Restoration of normal control mechanisms . J Natl Cancer Inst. 81:1989;982-987.
22. Sartorius CA, Tung L, Takimoto GS, Horwitz KB. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem. 268:1993;9262-9266.
23. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA. 90:1993;4441-4445.
24. Aronica SM, Katzenellenbogen BS. Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-I. Mol Endocrinol. 7:1993;743-752.
25. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci USA. 92:1996;4206-4210.
26. Fanidi A, Ahnadi C, Fayard JM, Pageaux JF, Laugier C. Opposite regulation of cAMP concentration in the quail oviduct and the mouse uterus by tamoxifen Correlation with estrogen-antagonist and estrogen-agonist activity . J Steroid Biochem Mol Biol. 41:1992;571-577.
27. 3) which mediates the antiestrogenic and antiproliferative effects of tamoxifen. Biochem Biophys Res Commun. 134:1986;601-608.
28. Lam PHY. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun. 118:1984;27-32.
29. Vignon F, Bouton M-M, Rochefort H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun. 146:1987;1502-1508.
30. Levin E, Actis AM, Lopez S. Characterization of rat uterine estrogen receptors in vivo. J Steroid Biochem Mol Biol. 44:1993;277-285.
31. King WJ, Greene GL. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature. 307:1984;745-747.
32. 3 cells. Endocrinology. 117:1986;2140-2147.
33. Ylikomi T, Bocquel MT, Berry M, Gronemeyer H, Chambon P. Cooperation of proto-signals for nuclear accumulation of estrogen and progesterone receptors. EMBO J. 11:1992;3681-3694.
34. LaCasse EC, Lochnan HA, Walker P, Lefebvre YA. Identification of binding proteins for nuclear localization signals of the glucocorticoid and thyroid hormone receptors. Endocrinology. 132:1993;1017-1025.
35. Guiochon-Mantel A, Lescop P, Christin-Maitre S, Loosfelt H, Perrot-Applanat M, Milgrom E. Nucleocytoplasmic shuttling of the progesterone receptor. EMBO J. 10:1991;3851-3859.
36. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol. 9:1995;659-669.
37. Campen CA, Jordan VC, Gorski J. Opposing biological actions of antiestrogens in vitro and in vivo Induction of progesterone receptor in the rat and mouse uterus . Endocrinology. 116:1985;2327-2336.
38. Levitzki A. Signal-transduction therapy A novel approach to disease management . Eur J Biochem. 226:1994;1-13.
39. Pennypacker KR. Pharmacological regulation of transcription factor binding. Pharmacology. 51:1995;1-12.